Molina to End Its Medicare Advantage Drug Plans on December 31. The Decision Was Announced in February. The Letter Telling Members Arrives in October
Molina Healthcare (MOH) will end its traditional Medicare Advantage prescription drug plans by December 31, 2026, affecting about 80,000 members. The company announced this decision in February 2026, but members were notified in October. Members must choose a new plan by December 7, 2026, to avoid losing coverage and potential penalties. Molina will retain its dual-eligible Medicare business, which generated $5 billion in 2025.
How this was made
The 30-second read
Why it matters
The announcement removes roughly $1 billion of premium revenue, likely leading to a downgrade of earnings forecasts and a negative reaction in the stock.
Market read
The news is material for MOH shareholders and may influence valuation of comparable Medicare Advantage insurers.
What to watch
Potential cost savings from exiting a low‑margin product and focus on higher‑margin dual‑eligible business.
Background
Molina Healthcare (NYSE:MOH) disclosed in its Q4 2026 earnings call that it will cease traditional MAPD plans after Dec 31 2026, retaining only its dual‑eligible business.
Ticker impact
Molina Healthcare announced it will exit its traditional MAPD plans, eliminating about $1 billion of premium revenue starting 2027.
downward pressure on the share price in the coming weeks
A $1 B revenue loss represents a material hit to earnings; investors will reassess guidance and may sell.
Market effects
May prompt scrutiny of other Medicare Advantage providers and could affect the broader health‑care services sector.
U.S. health‑care market, especially insurers with MAPD exposure, could see valuation adjustments.
Limited to U.S. markets; no direct global impact.
Counterpoint
If the dual‑eligible segment outperforms expectations, the net impact could be muted.
Key entities
- CompanyMolina Healthcare
U.S. Medicare Advantage insurer exiting MAPD plans.
